Forte Biosciences Projected to Report Q4 2025 Earnings

Analysts expect the biotech company to post a loss of $1.42 per share on Friday, March 27th.

Mar. 20, 2026 at 5:03am

Got story updates? Submit your updates here. ›

Forte Biosciences (NASDAQ:FBRX), a clinical-stage biotech company focused on developing treatments for skin conditions, is scheduled to release its Q4 2025 financial results before the market opens on Friday, March 27th. Analysts are projecting the company to report a loss of $1.42 per share for the quarter.

Why it matters

Forte Biosciences' upcoming earnings report will provide investors with the latest financial performance data and insights into the company's progress on its lead product candidate, FB-401, a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.

The details

Forte Biosciences is a clinical-stage biotech company headquartered in San Diego, California. The company is focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Forte's lead product candidate, FB-401, is currently in clinical trials for the treatment of atopic dermatitis.

  • Forte Biosciences will release its Q4 2025 earnings before the market opens on Friday, March 27, 2026.
  • The company's Q4 2025 earnings call is scheduled for Friday, March 27, 2026 at 4:00 PM ET.

The players

Forte Biosciences

A clinical-stage biotech company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Forte Biosciences' upcoming earnings report for updates on the company's financial performance and the progress of its lead product candidate, FB-401, in clinical trials.

The takeaway

Forte Biosciences' upcoming earnings report will provide important insights into the company's financial health and the development of its innovative skin health treatments, which could have significant implications for investors and the broader biotech industry.